Form 4: Enanta Pharma Executive Reports Tax-Related Stock Transactions
Insider Transaction Report
Kathleen S. Capps, Enanta Pharmaceuticals' Principal Accounting Officer, reported tax-related forfeitures and sales of common stock totaling 292 shares.
Summary
- Kathleen S. Capps, Executive Director of Accounting and Controller (Principal Accounting Officer) at Enanta Pharmaceuticals Inc. (ENTA), reported changes in beneficial ownership.
- On December 1, 2025, Capps forfeited 85 shares of common stock at $14.12 per share to cover withholding taxes related to a restricted stock unit (RSU) award granted on November 19, 2021.
- On December 2, 2025, Capps sold 207 shares of common stock at $13.96 per share to cover withholding taxes from an RSU award granted on November 27, 2024.
- These sales were explicitly noted as 'sell to cover' transactions to satisfy tax withholding obligations and do not represent discretionary transactions by the reporting person.
- Following these transactions, Capps beneficially owns 8,700 shares of Enanta Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The transactions are routine, non-discretionary 'sell to cover' actions for tax purposes related to restricted stock unit vesting. They do not indicate any positive or negative sentiment regarding the company's performance or future prospects.
Future Outlook
NA
Industry Context
These are routine insider transactions related to compensation and tax obligations, common across all industries for executives receiving equity awards. They do not reflect specific industry trends for biotechnology or pharmaceuticals.
Stakeholder Impact
- Shareholders: Minimal direct impact as these are routine tax-related transactions by an executive, not a discretionary sale indicating a change in confidence in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 2021-11-19 | Grant date of a restricted stock unit award to the reporting person. |
| 2024-11-27 | Grant date of a restricted stock unit award to the reporting person. |
| 2025-12-01 | Transaction date for the forfeiture of 85 shares of common stock to cover withholding taxes. |
| 2025-12-02 | Transaction date for the sale of 207 shares of common stock to cover withholding taxes. |
| 2025-12-03 | Signature date of the reporting person's attorney-in-fact for the filing. |
Recommendation
holdThe reported transactions are routine, non-discretionary 'sell to cover' actions by an executive to satisfy tax obligations upon the vesting of restricted stock units. These transactions do not reflect a change in the executive's confidence in the company's future or fundamental performance. Therefore, they do not provide a basis for changing an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.
Keywords
Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Kathleen S. Capps
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.